Completed PHASE3 INTERVENTIONAL 1-arm NCT02503163

A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome

Sponsor: Kissei Pharmaceutical Co., Ltd.

Conditions Dry Eye With Sjögren's Syndrome

Interventions KCT-0809 ophthalmic solution

Updated 6 times since 2017 Last updated: Nov 15, 2017 Primary completion: Oct 19, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02503163, this PHASE3 trial focuses on Dry Eye With Sjögren's Syndrome and remains completed. Sponsored by Kissei Pharmaceutical Co., Ltd., it has been updated 6 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Dec 2017 — Jun 2018 [monthly]

Completed PHASE3

Status: Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Dec 2017 [monthly]

Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kissei Pharmaceutical Co., Ltd.

Data source: Kissei Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Multiple Locations, Japan